［1］Anderson GL,Barrington WE.Narrowing of racial disparities in breast cancer incidence:Insights from menopausal hormone therapy study findings［J］.J Natl Cancer Inst,2016,108(4):djv393.
[2]Qiu SQ,Zeng HC,Zhang F,et al.A nomogram to predict the probability of axillary lymph node metastasis in early breast cancer patients with positive axillary ultrasound［J］.Sci Rep,2016,6:21196.
[3]Schwarzenbach H,Pantel K.Circulating DNA as biomarker in breast cancer［J］.Breast Cancer Research,2015,17(1):136.
[4]Hampton T.Circulating tumor DNA helps track cancer［J］.Journal of the American Medical Association,2016,315:19.
[5]Peter U,Martina A,Ellen H.Detection of circulating tumor DNA in the blood of cancer patients:An important tool in cancer chemoprevention［J］.Methods in Molecular Biology,2016,1379:45-68.
[6]Lianos GD,Mangano A,Cho WC,et al.Circulating tumor DNA:new horizons for improving cancer treatment［J］.Future Oncology,2015,11(4):545-548.
[7]Ryder CB,Schmotzer CL.Circulating tumor DNA:The future of personalized medicine in oncology［J］?Clinical Chemistry,2015,61(2):443.
[8]Gold B,Cankovic M,Furtado LV,et al.Do circulating tumor cells,exosomes,and circulating tumor nucleic acids have clinical utility?A report of the association for molecular pathology［J］.Journal of Molecular Diagnostics,2015,17(3):209-224.
[9]Mouliere F,Rosenfeld N.Circulating tumor-derived DNA is shorter than somatic DNA in plasma［J］.Proceedings of the National Academy of Sciences of the United States of America,2015,112(11):3178.
[10]Chetan Bettegowda,Mark Sausen,Rebecca Leary,et al.Detection of circulating tumor DNA in early and late stage human malignancies［J］.Science Translational Medicine,2014,6(224):224ra24.
[11]Ondrouková E,Hrstka R.Circulating tumor DNA in blood and its utilization as a potential biomarker for cancer［J］.Klin Onkol,2015,28(Suppl 2):69-74.
[12]García-Casas A,García-Olmo DC,García-Olmo D.Further the liquid biopsy:Gathering pieces of the puzzle of genometastasis theory［J］.World Journal of Clinical Oncology,2017,8(5):378.
[13]Saliou A，Bidard FC，Lantz O，et al．Circulating tumor DNA for triple-negative breast cancer diagnosis and treatment decisions［J］.Expert Rev Mol Diagn，2016，16(1):39-50.
[14]Caen O,Nizard P,Garrigou S,et al.Digital PCR compartmentalization II.Contribution for the quantitative detection of circulating tumor DNA［J］.Med Sci,2015,31(2):180-186.
[15]Carpinetti P,Donnard E,Bettoni F,et al.The use of personalized biomarkers and liquid biopsies to monitor treatment response and disease recurrence in locally advanced rectal cancer after neoadjuvant chemoradiation［J］.Oncotarget,2015,6(35):38360-38371.
[16]Benard A,van de Velde CJ,Lessard L,et al.Epigenetic status of LINE-1 predicts clinical outcome in early-stage rectal cancer［J］.British Journal of Cancer,2013,109(12):3073-3083.
[17]Taniguchi K,Uchida J,Nishino K,et al.Quantitative detection of EGFR mutations in circulating tumor DNA derived from lung adenocarcinomas［J］.Clinical Cancer Research,2011,17(24):7808-7815.
[18]Vallée A,Audigier-Valette C,Herbreteau G,et al.Rapid clearance of circulating tumor DNA during treatment with AZD9291 of a lung cancer patient presenting the resistance EGFR T790M mutation［J］.Lung Cancer,2015,91(2):73-74.
[19]Wise JE.(S036) Circulating tumor DNA and implications for clinical decision-making in stage I NSCLC［J］.Oncology,2015,29(4 Suppl 1):628-639.
[20]Goto T,Hirotsu Y,Oyama T,et al.Analysis of tumor-derived DNA in plasma and bone marrow fluid in lung cancer patients［J］.Medical Oncology,2016,33(3):29.
[21]Yrüker EE,zgür E,Keskin M,et al.Assessment of circulating serum DNA integrity in colorectal cancer patients［J］.Anticancer Research,2015,35(4):2435-2440.
[22]Tanaka T,Sakano A.Correlation of BRAF mutation status in circulating-free DNA and tumor and association with clinical outcome across four BRAFi and MEKi clinical trials［C］.Clin Cancer Res,2016:2771-2777.
[23]Bear HD,Tang G,Rastogi P,et al.Neoadjuvant plus adjuvant bevacizumab in early breast cancer(NSABP B-40 ［NRG Oncology］):Secondary outcomes of a phase 3,randomised controlled trial［J］.Lancet Oncol,2015,16(9):1037-1048.
[24]Payandeh M,Sadeghi M,Sadeghi E.Differences in prognostic factors between early and late recurrence breast cancers［J］.Asian Pac J Cancer Prev,2015,16(15):6575-6579.
[25]Garcia-Murillas I，Schiavon G，Weigelt B，et al．Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer［J］.Sci Transl Med，2015，7(302):302ra133.
[26]Schiavon G,Hrebien S,Garciamurillas I,et al.Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer［J］.Science Translational Medicine,2015,7(313):313ra182.
[27]Rothé F,Laes JF,Lambrechts D,et al.Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer［J］.Annals of Oncology,2014,25(10):1959.
[28]Murtaza M,Dawson SJ,Tsui DW,et al.Non- invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA［J］.Nature,2013,497(7447):108-112.
[29]Nagalingam A,Tighiouart M,Ryden L,et al.Med1 plays a critical role in the development of tamoxifen resistance［J］.Carcinogenesis,2012,33(4):918-930.
[30]Li F，Song ZJ，Wang CT，et al.Optimization of maintenance therapy for advanced breast cancer and analysis of clinical application of circulating tumor DNA［J］.Clinical Research and Practice,2017,2(24):09-10.［李飞，宋张骏，汪存涛，等.晚期乳腺癌维持治疗的优化及循环肿瘤DNA在临床的应用分析［J］.临床医学研究与实践，2017,2（24）：09-10.］
[31]Dawson SJ，Tsui DW，Murtaza M，et al．Analysis of circulating tumorDNA to monitor metastatic breast cancer［J］.N Engl J Med，2013，368(13):1199-1209.
[32]Hamakawa T，Kukita Y，Kurokawa Y，et al．Monitoring gastric cancer progression with circulating tumour DNA［J］.Br J Cancer，2015，112:352-356.
[33]Ma M,Zhu H,Zhang C,et al."Liquid biopsy"-ctDNA detection with great potential and challenges［J］.Annals of Translational Medicine,2015,3(16):235.